Table 1
Brief summary of the characteristics of the 4 NOACs.
| NOAC | Mechanism | Pivotal Trial | Year | Type of drug | Oral dosage form | Low or adjusted dose |
|---|---|---|---|---|---|---|
| Dabigatran | IIa inhibitor | RE-LY | 2009 | Capsule | 150 mg bid | 110 mg bid |
| Rivaroxaban | Xa inhibitor | ROCKET | 2011 | Tablet | 20 mg qd | 15 mg qd |
| Apixaban | Xa inhibitor | ARISTOTLE | 2011 | Tablet | 5 mg bid | 2.5 mg bid |
| Edoxaban | Xa inhibitor | ENGAGE | 2013 | Tablet | 60 mg qd | 30 mg qd |
Figure 1
The efficacy of NOACs versus warfarin in preventing stroke and systemic embolism in patients with non-valvular AF based on data from RCTs and studies reporting real-world data (RWD).
Figure 2
The risks of major bleeding in non-valvular AF patients treated with NOACs versus warfarin based on data from RCTs and studies reporting real-world data (RWD).